Asked by: Alison Bennett (Liberal Democrat - Mid Sussex)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many patients are being treated in temporary hospital environments, including corridors, for which the latest data is available.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
We recognise that the provision of clinical care in corridors or other non-designated clinical areas is unacceptable and are committed to eradicating it from our National Health Service.
Our Urgent and Emergency Care Plan, published in June 2025, set out steps we are taking to ensure that patients will receive better, faster, and more appropriate emergency care this winter, backed by a total of nearly £450 million of funding. This includes a commitment to publish data on the prevalence of corridor care.
NHS England has been working with trusts to put in place new reporting arrangements regarding the use of corridor care to drive improvement and data transparency. The data quality is currently being reviewed, and we expect to publish the information shortly.
We are also introducing new clinical operational standards for the first 72 hours of care, setting clear expectations for timely reviews and specialist input, further supporting our efforts to eliminate corridor care and improve patient experience.
In December, NHS England published updated guidance on providing care in corridors to support trusts with making decisions on corridor care transparently, with clear governance and oversight to reduce impacts on patients and staff and to ensure the safety and dignity of patients.
Asked by: Alison Bennett (Liberal Democrat - Mid Sussex)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the hospice sector on the financial viability of that sector.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
I attended the Hospice UK National Conference on 25 November 2025, where I heard directly from many people working in the hospice sector, including hospice chief executives and palliative care consultants and nurses. I really valued hearing their thoughts, insights, and expertise on the challenges facing the sector and how we can work together to come up with solutions.
I have also visited several hospices in recent months, including Sussex Beacon and Noah’s Ark Children’s Hospice, where I have had very informative discussions with hospice staff. Additionally, Department officials meet regularly with Hospice UK which provides updates on the financial state of the hospice sector at both national and local levels.
The Government is developing a Palliative Care and End-of-Life Care Modern Service Framework (MSF) for England. We will consider contracting and commissioning arrangements as part of our MSF. We recognise that there is currently a mix of contracting models in the hospice sector. By supporting integrated care boards to commission more strategically, we can move away from grant and block contract models. In the long term, this will aid sustainability and help hospices’ ability to plan ahead.
Officials are working closely with Hospice UK and a number of other stakeholders from the hospice sector in the development of the MSF.
Asked by: Alison Bennett (Liberal Democrat - Mid Sussex)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment the government has made of the potential impact of hospice cuts on quality of palliative care across the country.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Whilst the majority of palliative care and end-of-life care is provided by National Health Service staff and services, we recognise the vital part that voluntary sector organisations, including hospices, also play in providing support to people at the end of life and their loved ones.
Integrated care boards (ICBs) are responsible for commissioning palliative care and end-of-life care services that meet the needs of their local populations. To support ICBs in this duty, NHS England has published statutory guidance and service specifications. The statutory guidance states that ICBs must work to ensure that there is sufficient provision of care services to meet the needs of their local populations, which can include hospice services available within the ICB catchment.
NHS England has reinforced the requirement that, from April 2026, ICBs and relevant providers must have a full understanding of current and projected service utilisation and costs, including for those needing end-of-life care, to support sustainable planning. This will help systems to better assess local need and maintain quality of care.
The Government is also providing £125 million of capital funding for eligible adult, and children and young people’s hospices and we recently also confirmed approximately £80 million of revenue funding for the next three years for children and young people’s hospices in England.
Additionally, the Government is developing a Palliative Care and End-of-Life Care Modern Service Framework (MSF) for England. It will drive improvements in access, quality, and sustainability, and support ICB to commission high-quality, personalised care. Through our MSF, we will closely monitor the shift towards the strategic commissioning of palliative care and end-of-life care services, and we will also consider contracting and commissioning arrangements.
Asked by: Alison Bennett (Liberal Democrat - Mid Sussex)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that efforts to improve access to diagnosis and treatment for lipoedema adequality align with the Government’s commitments under the Women’s Health Strategy.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The refreshed Women’s Health Strategy will play a central role in improving outcomes for women living with long‑term conditions like lipoedema by addressing the systemic barriers that have historically contributed to delayed diagnosis, variability in care, and poorer health experiences.
The refreshed strategy places a strong emphasis on creating a healthcare system that listens to women, reduces diagnostic waiting times, and tackles entrenched inequalities, ensuring services are better aligned with women’s needs. By strengthening clinical awareness, supporting earlier and more accurate diagnosis, and embedding high‑quality, evidence‑based care across the system, the updated strategy, fully aligned with the 10‑Year Health Plan, will enhance support for women managing a wide range of long‑term conditions, including lipoedema.
Asked by: Alison Bennett (Liberal Democrat - Mid Sussex)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential factors that may prevent women from seeking diagnosis and referral for lipoedema; and what steps he is taking to ensure timely access to specialist assessment and treatment.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Women with lipoedema can face a number of barriers to seeking diagnosis and referral, including long waits, misdiagnosis, often as obesity or lymphoedema, and low awareness of the condition among both the public and some healthcare professionals. These factors can lead to delayed recognition, worsening symptoms, and reduced confidence in seeking care.
We recognise the need to improve awareness and understanding of lipoedema. To support earlier, more accurate diagnosis, the Royal College of General Practitioners (RCGP) has worked in partnership with Lipoedema UK to develop a dedicated e‑learning module for general practitioners, covering the presentation, pathophysiology, diagnosis, and management of lipoedema in primary care. This resource is freely available to RCGP members.
Access to specialist assessment and treatment for lipoedema is commissioned locally by integrated care boards, which are best placed to understand local population need. Treatment options may include compression therapy, simple lymphatic drainage, self‑management support and, in severe cases, consideration of liposuction in line with interventional procedures guidance published by the National Institute for Health and Care Excellence (NICE). Clinicians may offer treatment where appropriate, using their professional judgment and taking advice published by NICE into account.
We are aware that some European countries, including Germany, have expanded access to liposuction for lipoedema following emerging evidence from the German LiPLEG study into liposuction. In England, NICE’s current guidance advises that evidence on the safety and efficacy of liposuction for chronic lipoedema remains limited, and it should only be offered with appropriate clinical governance and safeguards. NICE will review this guidance once the full LiPLEG data is available.
Asked by: Alison Bennett (Liberal Democrat - Mid Sussex)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has considered adopting approaches to lipoedema treatment used by other European countries, like Germany and Spain.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Women with lipoedema can face a number of barriers to seeking diagnosis and referral, including long waits, misdiagnosis, often as obesity or lymphoedema, and low awareness of the condition among both the public and some healthcare professionals. These factors can lead to delayed recognition, worsening symptoms, and reduced confidence in seeking care.
We recognise the need to improve awareness and understanding of lipoedema. To support earlier, more accurate diagnosis, the Royal College of General Practitioners (RCGP) has worked in partnership with Lipoedema UK to develop a dedicated e‑learning module for general practitioners, covering the presentation, pathophysiology, diagnosis, and management of lipoedema in primary care. This resource is freely available to RCGP members.
Access to specialist assessment and treatment for lipoedema is commissioned locally by integrated care boards, which are best placed to understand local population need. Treatment options may include compression therapy, simple lymphatic drainage, self‑management support and, in severe cases, consideration of liposuction in line with interventional procedures guidance published by the National Institute for Health and Care Excellence (NICE). Clinicians may offer treatment where appropriate, using their professional judgment and taking advice published by NICE into account.
We are aware that some European countries, including Germany, have expanded access to liposuction for lipoedema following emerging evidence from the German LiPLEG study into liposuction. In England, NICE’s current guidance advises that evidence on the safety and efficacy of liposuction for chronic lipoedema remains limited, and it should only be offered with appropriate clinical governance and safeguards. NICE will review this guidance once the full LiPLEG data is available.
Asked by: Alison Bennett (Liberal Democrat - Mid Sussex)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential role of GLP-1 medications in reducing inflammation and pain associated with lipoedema.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not made any assessment of the potential role of GLP-1 medications in reducing inflammation and pain associated with lipoedema. Newly licensed medicines are appraised by the National Institute for Health and Care Excellence (NICE), which is the independent body responsible for developing evidence-based guidance for the National Health Service on which new medicines represent a clinically and cost-effective use of resources. NICE only makes recommendations on medicines within their licensed indications, and there is no GLP1 inhibitor with a United Kingdom marketing authorisation for use in the treatment of lipoedema. If a manufacturer applies for a UK marketing authorisation it may then be considered for evaluation by NICE.
In the absence of NICE guidance, clinicians are able to prescribe a medicine if they consider it appropriate for their patients, subject to funding being available. NHS commissioners are expected to make funding decisions based on an assessment of the available evidence.
Asked by: Alison Bennett (Liberal Democrat - Mid Sussex)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how his department will assist post-radiotherapy head and neck cancer patients who currently have to pay for private dentistry due to a lack of NHS dentistry places, despite regular check-ups being an essential part of their post-radiotherapy care.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
To assist post-radiotherapy head and neck cancer patients, dentists will prioritise patients at a higher risk of oral cancer for more frequent recall and review in line with National Institute for Health and Care Excellence (NICE) guidance.
Members of the public who are worried about their oral health in relation to cancer, including post-radiotherapy head and neck cancer patients, should seek advice from their dentist or general practitioner (GP). Patients with symptoms of concern should be assessed and offered an urgent dental appointment based upon clinical need, in line with advice from NHS England.
Some people are eligible for exemptions from NHS dental patient charges, or help with part of the cost of treatment, including those who are receiving certain benefits. Further information is available at the following link:
https://www.nhs.uk/nhs-services/dentists/who-can-get-free-nhs-dental-treatment/
Asked by: Alison Bennett (Liberal Democrat - Mid Sussex)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase resourcing for the Sussex Endometriosis Centre in Mid Sussex constituency.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The specialist service at the Sussex Endometriosis Centre, run by the University Hospitals Sussex NHS Foundation Trust, has experienced some workforce challenges with the dedicated staff for this service.
However, NHS England continues to work closely with providers, including the University Hospitals Sussex NHS Foundation Trust, to support further improvements in waiting times and remains committed to working towards delivery of the ambitions set out by the Government, including eliminating long waits for patients.
The Government is committed to publishing a 10 Year Workforce Plan which will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it.